Observation is required for infusion-related reactions and hypersensitivity reactions, including anaphylaxis during and at least up to one hour following infusion completion.

Casirivimab and imdevimab are not renally excreted or metabolized by cytochrome P450 enzymes. Therefore, interactions are unlikely when given together with medications that are renally excreted or that are inducers, substrates, or inhibitors of cytochrome P450 enzymes.